Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine

Pharmacotherapy

Volumn 20, Issue 11, 2000, Pages 1356-1364

  Biddle, Andrea K ^a   Shih, Ya Chen Tina ^b,c   Kwong, W Jacqueline ^a,d  

^a School of Public Health ^*  (United States)

^b University of North Carolina   (United States)

^c UNITED BIOSOURCE CORPORATION   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIMIGRAINE AGENT; BUTALBITAL; BUTORPHANOL TARTRATE; CAFERGOT; ERGOTAMINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; ISOMETHEPTENE MUCATE; METOCLOPRAMIDE; NAPROXEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; SEROTONIN 1 AGONIST; SUMATRIPTAN SUCCINATE; WIGRAINE;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG INDUCED DISEASE; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MANAGED CARE; MEDICAL DECISION MAKING; MIGRAINE; PAIN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

ABSENTEEISM; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS;

EID: 0033765272     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.17.1356.34890     Document Type: Article

References (29)

1. Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemographic factors
2. Impact of migraine in the United States: Data from the national health interview survey
3. Healthcare resource and lost labour costs of migraine headache in the U.S.
4. Measuring the functional status and well-being of patients with migraine headache
5. Oral sumatriptan for the acute treatment of migraine: Dose-ranging data
6. Oral sumatriptan is effective and well tolerated in the acute treatment of migraine: Results of a multicenter study
7. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study
8. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study
9. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
10. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine
11. A multinational investigation of the impact of subcutaneous sumatriptan. I. Design, methods and clinical findings
12. Impact of oral sumatriptan on workplace productivity, health-related quality of life, healthcare use, and patient satisfaction with medication in nurses with migraine
13. HMO direct costs and health care resource use after implementation of a monthly limit on sumatriptan
14. Clinical and financial implications of migraine in a managed care setting
15. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine
16. Comparing dihydro-ergotamine mesylate and sumatriptan in the management of acute migraine
17. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?
18. Healthcare resource use and costs associated with migraine in a managed healthcare setting
19. Sumatriptan injection reduces productivity loss during a migraine attack
20. Migraine heterogeneity: Disability, pain intensity, and attack frequency and duration
21. The willingness to pay for in vitro fertilization: A pilot study using contingent valuation
22. Burden of migraine in the United States: Disability and economic costs
23. Charges vs. reimbursement: The gap widens again
24. Quality-of-life assessment in patients with headache
25. Sumatriptan treatment for migraine in a health maintenance organization: Economic, humanistic, and clinical outcomes